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Introduction
The growth hormone insulin like growth factor-1
(GH-IGF-1) axis is the key regulator of somatic growth in
humans. Adult height is controlled by genetic and 
non-genetic factors. Common variants in genes of  the 
GH-IGF-1 axis  contribute to height variation in the general
population (1). Genetic variations in the GH-IGF-1 axis might
also affect the response to GH treatment.  GH action is
mediated through the activation of its surface receptor, GH
receptor (GHR), a 620 amino acid single-transmembrane
protein. The binding of GH to GHR results in the formation
of a receptor homodimer. Interaction of dimerized GHR with
intracellular tyrosine kinase JAK-2 leads to the phosphorylation
of downstream signal transduction molecules, induction of
signal transducers and activators of transcription (STAT) 
proteins, and stimulation of mitogen-activated protein (MAP)
kinases. Activated STAT5 is then translocated to the 
nucleus where it transactivates the expression of IGF-1 and
other GH-dependent genes (2,3,4). 
GHR gene is located on the short arm of chromosome 5
(p13.1-p12) (5,6). It consists of  nine coding exons (exon 
2-10) and several untranslated exons; exon 2 codes for the
signal peptide, exon 3-7 encode the extracellular domain,
exon 8 encodes the transmembrane domain, and exon 9-10
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may affect the response to exogenous GH treatment in
patients with short stature due to differences in GH 
pharmacogenetics. Polymorphisms in the GHR gene have
been described for exons 3, 6 and 10 (7). Two of the most
common GHR isoforms in humans are generated by 
retention (fl-GHR) or deletion (d3-GHR) of exon 3, which
encodes a sequence in the extracellular domain. In the
Caucasian population, the frequency of fl-GHR has been
estimated to range from 56% to 75% and that of d3-GHR
from 25% to 44% (8,9,10,11,12). In Asian populations, 
d3-GHR allele was found to be less frequent (13,14,15). 
The aim of this study was to evaluate the distribution of
GHR exon 3 polymorphisms in the Turkish population. 
Materials and Methods
The study included 477 (54 females/423 males) healthy
adults. The volunteers were recruited from blood donors and
hospital staff. Mean±SD age was 31.1±9.0 years (range: 
18-57). None of the subjects had received therapy with GH or
any other anabolic drug. A single subject per family was
included in the study. Height and weight were measured by
standard methods and body mass index (BMI) was calculated
as weight (kg)/height (m)2.  Height, weight and BMI were
expressed as standard deviation score (SDS) (16,17). Height
and BMI SDSs were within normal ranges (between - 2 and +
2 SD) in all subjects.  Blood samples were taken from all sub-
jects for measurement of  IGF-1 and IGF binding protein-3
(IGFBP-3) and for isolation of DNA. 
IGF-1 (ng/mL) was measured by IRMA method 
(DSL-5600, Webster, Tx). The limit of sensitivity was 0.80
ng/mL. Intra and inter-assay coefficient of variation (CV) 
values  were 1.5-3.4% and 1.5-8.2%, respectively. IGFBP-3
(ng/mL), also measured by IRMA method (DSL- 6600,
Webster, Tx), has a limit of sensitivity of 0.5 ng/mL. 
Intra and inter-assay CV were 1.8–3.9% and 0.5–1.9%,
respectively. IGF-1 and IGFBP-3 SDSs were calculated
using reference values of the IGF-1 and IGFBP-3 assays
(http://www.beckmancoulter.com). 
Subanalysis was carried out by grouping the patients
according to their height SDS as the tallest (+2 and >+1),
the average (≤+1 and >-1), and the shortest (≤-1 and ≥-2)
height groups.
Molecular Analysis
Genomic DNA was isolated from peripheral blood 
leucocytes of healthy adults by DNA isolation kit (MagNA
pure kit, Roche Diagnostics, Mannheim, Germany) in
Istanbul Faculty of Medicine at Istanbul University.
The frequency of the GHR transcript variant [full length
(fl) or exon 3 deleted (d3)] was tested by a simple multiplex
polymerase chain reaction (PCR) assay, using one sense
primer (G1) and two antisense primers one specific for
GHRfl (G3) and the other specific for GHRd3 isoform (G2)
(GenBank accession number AF155912), as described by
Pantel et al (8). Amplification products were analyzed by
electrophoresis on 1% agarose gel stained with ethidium
bromide. The fl allele is represented by a 935-bp fragment
and the d3 allele by a 532-bp fragment. A second PCR
assay for samples initially genotyped as homozygous
GHRd3 (d3/d3), using the primer specific to the GHRfl 
isoform (G1 and G3), was performed to avoid false 
homozygous GHRd3 genotyping.
Ethics
This study was approved by the local ethics committee.
Written informed consent was obtained from all subjects. 
Statistical Analysis
Statistical analyses were done using SPSS version 12.0
(SPSS Inc., Chicago, IL). Values are expressed as
mean±SD. Comparison between the means was done by
parametric tests. Height SDS in the healthy adults was 
analyzed for normal distribution by the Kolmogorov-Smirnov
test (χ2=0.085, p=0.000). Hardy-Weinberg equilibrium
(HWE) was calculated according to standard procedures
using  χ2 analysis.  Differences between the variables 
evaluated among the d3/fl-GHR genotypes were calculated
using ANOVA (Bonferroni). Differences for the d3/fl-GHR
genotype frequencies were analyzed by the χ2 test. A 
p-value of less than 0.05 was considered statistically 
significant. 
Results
The distribution of the three GHR exon 3 genotypes in
this Turkish healthy adult population was  35% (n=167) for
fl/fl, 39% (n=186) for fl/d3, and 26% (n=124) for d3/d3.
There was no difference between genders with respect to
the distribution of these three GHR exon 3 genotypes.
There were also no differences in height and BMI SDSs
among the three d3/fl-GHR genotype groups. IGFBP-3 SDS
was significantly higher in the fl/d3 group as compared to
the fl/fl group (p=0.022) (Table 1). 
Genotype frequencies reached HWE only in the tallest
height group, but not in the average and the shortest height
groups. In the total population, frequencies of fl allele 
and d3 allele were  54.5% (n=520) and 45.5% (n=434),
respectively. Allele frequencies were similar in the three
height groups. There were no differences in genotypes or
in IGF-1 and IGFBP-3 SDS values among subjects grouped
according to their height SDS. IGF-1 SDS was found to be
higher in the tallest height group, but this difference was
not significant (Table 2). 
127
Baﬂ F et al.
Growth Hormone Receptor Exon 3There was a positive significant correlation between BMI
SDS and IGFBP-3 SDS  in all groups (r=0.114, p=0.025).
Discussion
Adult height is not determined by a single gene but by
complex polygenic inheritance. Studies in adult twins have
shown that differences in height are related by 75-89% to
genetic factors (18,19). Genetic influences on birth 
length and postnatal growth are still being studied (20).
Genome-wide analysis is expected to facilitate the 
discovery of new genes related to somatic growth and to
reveal the extent of impact of known genes. GHR exon 3
genotypes constitute the first genetic factor shown to
affect the response to GH therapy (10). However, 
subsequent studies about the extent of this effect have
been inconclusive (3). 
Studies aiming to show the effects of GHR exon 3
genotypes on the height differences among populations
revealed that the frequency of d3 allele was high among 
the Caucasian population (8,11,21),  but low in Asian 
populations (14,15,22).
In our study, the frequencies of GHR exon 3 genotypes
were 35% for fl/fl, %39 for fl/d3, 26% for d3/d3. The fl allele
frequency was 54.5%, while the d3 allele frequency was
45.5%.  No difference was found in the distribution of GHR
exon 3 genotypes among the shortest height group (height
SDS between -1 and -2) and the other groups. Neither the
total group nor any  height group, except for the tallest
height group, reached HWE. GHR exon 3 genotype and
allele frequencies were similar to those of European adults
with normal stature and the homozygous d3 genotype was
slightly more frequent (Table 3).
Kenth et al (23) reported a GHR exon 3 genotype 
distribution similar to our study, although they found a
slightly higher (53.3%) fl/fl frequency and a slightly lower
(11.1%) d3/d3 frequency. The authors reported an fl/d3 
frequency of 35.9%. They failed to demonstrate an 
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Table 1. Clinical and laboratory findings in different GHR exon 3 genotypes
(mean±SD) 
GHR exon 3 genotype fl/fl fl/d3 d3/d3
n (%) 167 (35) 186 (39) 124 (26)
Age (years) 30.1±9.3 31.7±8.5 31.8±9.2
Males/Females 147/20 168/18 108/16
Height SDS -0.3±0.8 -0.2±0.9 -0.3±0.9
BMI SDS 0.8±1.1 0.8±1.1 0.8±1.1
IGF-1 SDS -0.95±1.2           -0.4±3.3 -0.5±2.6
IGFBP-3 SDS -0.7±1.6 * -0.1±1.7 -0.4±1.9
* fl/fl vs. fl/d3 : p=0.022
fl = full length, d3 = exon 3 deleted, SDS: standard deviation score, BMI: body mass
index, IGF-1: insulin-like growth factor-1, IGFBP-3: IGF binding protein-3, GHR:
growth hormone receptor
Table 2. Clinical and laboratory findings in the subgroups with respect to height SDS (mean±SD values and percentages)
≤ +2 and >+1 ≤+1 and >-1  ≤-1 and ≥-2
Height groups (tallest group) (average group) (shortest group) Total group
n (%) 35 (7.1) 351 (71.2) 91 (18.5) 477
Males/Females 30/5 309/42 84/7 423/54
Age (years) 31.4±9.7 30.9±9.0 31.8±8.6 31.1±9.0
Frequency n (%) fl/fl 10 (28.6) 129 (36.8) 28 (30.8) 167 (35)
fl/d3 13 (37.1) 139 (39.6) 34 (37.4) 186 (39)
d3/d3 12 (34.3) 83 (23.6) 29 (31.8) 124 (26)
IGF-1 (SDS) -0.01±3.4 -0.6±2.7 -0.8±1.0 -0.6±2.5
IGFBP-3 (SDS) -0.1±1.9 -0.4±1.8 -0.4±1.6 -0.4±1.7
fl allele frequency % 47.1 56.6 49.5 54.5
d3 allele frequency % 52.9 43.4 50.5 45.5
HWE χ2 (p)‡ 2.27 (0.131) 13.228 (<0.001) 5.809 (0.015) 21.79 (<0.0001)
‡Hardy-Weinberg equilibrium
fl: full length, d3: exon 3 deleted, SDS: standard deviation score, IGF-1: insulin-like growth factor-1, IGFBP-3: IGF binding protein-3, GHR: growth hormone receptorassociation of adult height with BMI values and GHR 
genotype. Raz et al (24) investigated GHR exon 3 genotype
distribution in 211 Swedish adults with normal stature. The
frequencies they estimated for the total group were 47.9%
for fl/fl,  43.6% for fl/d3 and 8.5% for d3/d3. In addition,
when the authors examined their sample by subgroups
based on height, they found that d3/d3 frequency was 
higher (13.1%) in the tallest subgroup (height SDS between
+2 and +1) as compared to the total group and to the other
subgroups. In comparison with the total group, d3 allele 
frequency was slightly higher in the tallest height group
(37% vs. 30%). In our study, d3/d3 genotype and d3 allele
frequency were slightly higher in the tallest group, but this
difference was not statistically significant.
Audi et al (21) investigated GHR exon 3 genotype 
distribution among 247 small for gestational age (SGA) 
children and adolescents with short stature and among 289
adults with a height SDS between -2 and +2 SD. In this
study, the frequency of genotypes in the adult group was
reported as 27% for fl/fl, 57.8% for fl/d3 and 15.2% for
d3/d3. The adults were divided into height subgroups, as
tall (+2 and +1 SD), average height (+1 and -1 SD) and short
(-1 and -2 SD). Among all adults, the estimated d3 and fl
allele frequencies were 44% and 56%, respectively.
Genotype distribution reached HWE in the total group, in
the tall group and the short group.  In SGA children with
short stature, the frequency of genotypes was fl/fl 44.2%,
fl/d3 44.5%, d3/d3  11.3%; d3 allele  34%, and fl 
allele 66%. The fl/d3 genotype was found to be more 
common. In contrast, d3/d3 genotype frequency in shortest
height group (fl/fl 25%, fl/d3 68.3%, d3/d3 6.7%, d3 allele
frequency 41%, fl allele frequency 59%) was low. The 
biologically less active fl/fl genotype was reported as twice
more frequent in SGA patients with short stature.
Compared to other studies conducted in Europe, the 
reported frequency of fl/fl genotype in adults was slightly
lower. Based on these findings, the authors concluded that
d3/fl GHR exon 3 polymorphism may have an impact 
on height.  
Millar et al (25) compared an African Beninese 
population, which has a low mean height, and an English
population in terms of GHR exon 3 genotype distribution.
They observed that the Benineses had a significantly 
higher d3/d3 frequency (47% vs. 28%). Furthermore, d3/fl
and fl/fl genotypes were also found to be higher among the
Beninese than among the English population (70% vs.
47%). GHR exon 3 distribution did not reach HWE in either
English or Beninese populations studied. The authors 
suggested that the higher incidence of GHR exon 3 deletion
polymorphism among Benineses and the increase of GH1
expression and GHR-mediated growth response can be
regarded as an adaptive response to famine and insufficient
nutrition.
In our study, although there was no difference among
the genotype groups in terms of BMI SDS and IGF-1 SDS,
the subjects with  heterozygous GHR exon 3 polimorphism
had significantly higher IGFBP-3 SDS. There was a 
significant positive correlation between BMI SDS and
IGFBP-3 SDS. Recent studies have assessed the 
interaction between efficacy of GH therapy and GHR exon
3 polymorphisms in various groups of GH deficient (GHD)
patients (26,27,28). The results in GHD children are 
conflicting. One study found a higher growth velocity in the
group bearing at least one d3-GHR allele (26), whereas two
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Table 3. The distribution of GHR exon 3 genotypes in different populations
Study GHR genotype Allele frequencies
First author, year of  Country n fl/fl (%) fl/d3 (%) d3/d3 (%) fl (%) d3 (%) 
publication, reference number
Present study Turkey 477 35 39 26 54.5 45.5
Pantel, 2000 (8) France 150 58 33 9 75 25
Binder, 2006 (11) Germany 62 45 40 15 65 35
Audi, 2006 (21) Spain 289 27 57.8 15.2 56 44
Kenth, 2007 (23) Canada 368 53.3 35.6 11.1 71.4 28.6
Raz, 2008 (24) Switzerland 211 47.9 43.6 8.5 70 30
Millar, 2008 (25)  Benin  154 30 44 26 53 47
Adetunji, 2009 (31) UK 100 53 40 7 73 27
fl : full length, d3: exon 3 deleted, GHR: growth hormone receptorother studies did not show this relationship (27,28). In the
study of adult GHD patients, van der Klaauw et al (29) found
a considerable increase in IGF-1 in patients bearing d3-GHR
allele at short-term follow-up. In a study of 124 GHD adults,
Barbosa et al (30) observed no influence of the d3-GHR
allele on the response to GH therapy. The different results
in the studies carried out in children and in adults highlight
the risk of false negativity or positivity due to the interfer-
ence of several factors on genotype-phenotype interac-
tions. Only prospective and larger studies including a homo-
geneous group of GHD patients bearing all GHR 
genotypes in a significant number, with similar inclusion
and exclusion criteria as well as a similar therapeutic
approach, would clarify the contribution of d3-GHR to the
response to GH therapy.
In conclusion, this study presents the results of GHR 
polymorphism in a Turkish population as a reference for 
further studies. The distribution was similar to that in
European populations. There were no correlations between
heights of the individuals and GHR isoforms except for a 
higher IGFBP-3 in the fl/d3 group as compared to the fl/fl group. 
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